Generation Bio Co. (NASDAQ:GBIO) Insider Douglas Kerr Sells 14,072 Shares of Stock

Generation Bio Co. (NASDAQ:GBIO) insider Douglas Kerr sold 14,072 shares of the stock in a transaction that occurred on Monday, April 5th. The stock was sold at an average price of $30.09, for a total value of $423,426.48. Following the transaction, the insider now owns 340,630 shares in the company, valued at $10,249,556.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Douglas Kerr also recently made the following trade(s):

  • On Monday, January 11th, Douglas Kerr sold 11,267 shares of Generation Bio stock. The shares were sold at an average price of $27.58, for a total transaction of $310,743.86.

Shares of NASDAQ:GBIO opened at $28.55 on Thursday. The business’s 50 day moving average is $33.17 and its 200 day moving average is $31.78. Generation Bio Co. has a 12-month low of $17.00 and a 12-month high of $55.72.

Generation Bio (NASDAQ:GBIO) last posted its quarterly earnings data on Wednesday, March 17th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.23. As a group, research analysts predict that Generation Bio Co. will post -2.89 earnings per share for the current fiscal year.

A number of equities research analysts have commented on GBIO shares. JPMorgan Chase & Co. raised their price target on shares of Generation Bio from $34.00 to $39.00 and gave the stock an “overweight” rating in a report on Monday, March 22nd. Needham & Company LLC started coverage on Generation Bio in a research note on Thursday, February 25th. They set a “buy” rating and a $50.00 price target on the stock. Finally, William Blair started coverage on Generation Bio in a research note on Monday, March 1st. They issued an “outperform” rating and a $45.00 price objective for the company. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $40.60.

Hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN bought a new stake in Generation Bio during the third quarter worth $291,000. California Public Employees Retirement System bought a new position in shares of Generation Bio during the 3rd quarter worth $768,000. BlackRock Inc. increased its holdings in Generation Bio by 3,342.3% in the 3rd quarter. BlackRock Inc. now owns 671,243 shares of the company’s stock worth $20,747,000 after acquiring an additional 651,743 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in Generation Bio in the 3rd quarter valued at about $203,000. Finally, State Street Corp purchased a new stake in Generation Bio during the third quarter valued at about $4,456,000. 63.26% of the stock is owned by institutional investors and hedge funds.

Generation Bio Company Profile

Generation Bio Co, a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.

Further Reading: Neutral Rating

Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with's FREE daily email newsletter.